Find Zoldonrasib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Xj52bwk3xe, 3034802-05-3, Refchem:1101199, Kras g12d inhibitor 18, 2922732-54-3, Rmc-9805
Molecular Formula
C63H88F3N11O7
Molecular Weight
1168.4  g/mol
InChI Key
VKNNQJWNUPSOEK-VCAAAJMFSA-N
FDA UNII
XJ52BWK3XE

Zoldonrasib
Zoldonrasib is an orally bioavailable covalent tri-complex inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, zoldonrasib specifically targets and non-covalently binds to cyclophilin A to form a non-covalent binary complex, which subsequently covalently and irreversibly binds to the active GTP-bound form of KRAS G12D (KRASG12D(ON)). This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This causes apoptosis in KRAS G12D-expressing tumor cells. In addition, inhibition of KRAS G12D signaling by zoldonrasib abrogates the suppressive tumor microenvironment (TME) and enhances an anti-tumor immune response which further leads to an inhibition of proliferation of KRAS G12D-expressing tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.
1 2D Structure

Zoldonrasib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-cyclopentyl-2-[(5S)-2-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-7-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide
2.1.2 InChI
InChI=1S/C63H88F3N11O7/c1-39(82-5)52-47(30-44(33-67-52)72-25-23-71(24-26-72)42-14-15-42)55-48-32-61(2,3)38-84-60(81)49-11-8-20-77(69-49)58(79)50(31-45-34-73(27-28-83-45)43-16-17-51(46(48)29-43)76(55)37-63(64,65)66)68-57(78)54(40-9-6-7-10-40)74-21-18-62(35-74)19-22-75(36-62)59(80)56-53(70(56)4)41-12-13-41/h16-17,29-30,33,39-42,45,49-50,53-54,56,69H,6-15,18-28,31-32,34-38H2,1-5H3,(H,68,78)/t39-,45-,49-,50-,53+,54-,56+,62-,70?/m0/s1
2.1.3 InChI Key
VKNNQJWNUPSOEK-VCAAAJMFSA-N
2.2 Other Identifiers
2.2.1 UNII
XJ52BWK3XE
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Xj52bwk3xe

2. 3034802-05-3

3. Refchem:1101199

4. Kras G12d Inhibitor 18

5. 2922732-54-3

6. Rmc-9805

7. Rmc9805

8. Zoldonrasib [inn]

9. Zoldonrasib [usan]

10. Orb1944618

11. Schembl26348957

12. Gtpl13482

13. Rmc 9805 [who-dd]

14. Ex-a8179

15. Rmc 9805

16. Rmi-5921

17. Nsc856258

18. At45104

19. Nsc-856258

20. Ac-38191

21. Da-54679

22. Example A26 [wo2023060253a1]

23. Hy-156819

24. Cs-0897768

25. (2s)-2-cyclopentyl-2-{(5s)-7-[(2r,3r)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-2-yl}-n-[(12m,22s,4s,63s)-12-{5-(4-cyclopropylpiperazin-1-yl)-2-[(1s)-1-methoxyethyl]pyridin-3-yl}-10,10-dimethyl-5,7-dioxo-11-(2,2,2-trifluoroethyl)-11h-8-oxa-1(5,3)-indola-2(4,2)-morpholina-6(1,3)-[1,2]diazinanacycloundecaphan-4-yl]acetamide

2.4 Create Date
2023-05-30
3 Chemical and Physical Properties
Molecular Weight 1168.4 g/mol
Molecular Formula C63H88F3N11O7
XLogP37.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count17
Rotatable Bond Count12
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area160
Heavy Atom Count84
Formal Charge0
Complexity2370
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty